Stanley Medical Research Institute: Regular Treatment Trials in Schizophrenia and Bipolar Disorder
| Name: |
Stanley Medical Research Institute: Regular Treatment Trials in Schizophrenia and Bipolar Disorder Application deadline: 01/10/13 |
|---|---|
| General description: |
The purpose of this program is to support the testing of medications to assess their efficacy for treating schizophrenia and bipolar disorder. SMRI is especially interested in supporting the testing of medications that are unlikely to be tested by pharmaceutical companies because they are not commercially profitable. At any given time, SMRI is supporting 75-100 treatment trials, the majority of which are on generic and/or off-label medications. Funding: up to $300K/year. |
| Source: | Foreign |
| Budget: |
Funding: up to $300K/year. |
| Contact person: | Robi, 2152, robertg@trdf.technion.ac.il; Rivka, 2354, rivkag@trdf.technion.ac.il |
| Fields: | Life Sciences and medicine |
| Related fund and profiles: | , |